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Abstract: Parkinson’s disease (PD) is primarily a motor 
disorder that involves the gradual loss of motor function. 
Symptoms are observed initially in the extremities, such 
as hands and arms, while advanced stages of the disease 
can effect blinking, swallowing, speaking, and breathing. 
PD is a neurodegenerative disease, with dopaminergic 
neuronal loss occurring in the substantia nigra pars com-
pacta, thus disrupting basal ganglia functions. This leads 
to downstream effects on other neurotransmitter systems 
such as glutamate, g-aminobutyric acid, and serotonin. To 
date, one of the main treatments for PD is levodopa. While 
it is generally very effective, prolonged treatments lead to 
levodopa-induced dyskinesia (LID). LID encompasses a 
family of symptoms ranging from uncontrolled repetitive 
movements to sustained muscle contractions. In many 
cases, the symptoms of LID can cause more grief than PD 
itself. The purpose of this review is to discuss the possible 
clinical features, cognitive correlates, neural substrates, 
as well as potential psychopharmacological and surgical 
(including nondopaminergic and deep brain stimulation) 
treatments of LID.
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Introduction
Levodopa-induced dyskinesia (LID) is a complication that 
arises in Parkinson’s disease (PD). The severity of LID can 
vary, as in many cases they can be more problematic than 
the original PD symptoms. While it is generally believed 
that LID is linked to extended dopamine (DA) therapy (i.e. 
levodopa), there are multiple factors that contribute to the 
incidence of the condition. There are also multiple phar-
macological treatments that have been shown to be effec-
tive in patients and animal models of LID. Our aim is to 
illustrate the variety of theories underlying LID and cover 
a range of treatments, further highlighting the range of 
neurotransmitters, cortical and subcortical areas that play 
a role in LID. We will begin with the clinical features of LID 
and various risk factors that increase the patient’s chance 
of experiencing LID. We will then discuss the neural sub-
strates that have been shown to have abnormal function-
ing in PD patients or have an effect on LID symptoms. We 
will then review a number of pharmaceutical and surgical 
treatments that were shown to ameliorate LID symptoms.
Clinical features and findings in 
primate models of PD
While most PD patients undergo levodopa treatment, the 
reported incidence rate of LID is approximately 30%–80% 
(Fabbrini et  al., 2007). The large variance is due to the 
many factors that contribute to the risk of developing LID, 
which include gender (Zappia et al., 2005), age of onset of 
PD (Kumar et al., 2005), duration of levodopa treatment, 
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the size of the dosage (Zappia et al., 2005), and genetics 
(Kaplan et al., 2014; Rieck et al., 2015). Additionally, meth-
odological variations in measuring LID (e.g. self-report 
detection vs. detection by a thorough neurological exami-
nation) and a lack of a standardized test may explain the 
differences among the different reports of LID.
LIDs are heterogeneous, usually presenting as range if 
involuntary movements. The most common are described 
by chorea (accidental, rapid, irregular, and aimless 
motions that seem to flow from one part in the body to 
another) and dystonia (sustained muscle contractions). 
Uncommon forms of LID include akathasia (excessive 
motor restlessness), blepharospasm (involuntary contrac-
tion of the eyelid muscles), a high stepped overshooting 
gait, rapid alternating motions of legs, and mixed pattern 
of abnormal movements (Fahn, 2000), respiratory, and 
ocular dyskinesia (Fabbrini et  al., 2007). Further, LID 
tends to develop first on the side most affected by PD and 
will more often appear in the legs before the arms (Sacks 
et al., 1970; Ballard et al., 1985). This could be relevant to 
early dopaminergic damage in dorsolateral striatum, the 
region related to leg movement control (Fahn, 2000).
It is widely known that dyskinesias appear after dopa-
minergic therapy and that a time lag is present between the 
start of treatment and the appearance of LID. While dyski-
nesias are more often associated with levodopa, there are 
reports that have found that other DA agonists can cause 
dyskinesia (Rascol et al., 2000). Rascol et al. (2000) found 
that after 5 years of treatment, the occurrence of dyskine-
sia regardless of levodopa supplementation was 20% in a 
group of PD patients on ropinirole and 45% in a group of PD 
patients on levodopa. Similar results have been reported 
using pramipexole (Holloway et al., 2004). Interestingly, a 
recent study found that the rates of dyskinesia were similar 
in PD patients treated with levodopa in comparison to 
patients treated with DA agonists or inhibitors for monoam-
ine oxidase B (MAOB), a DA degrading enzyme (Gray et al., 
2014). As we discuss below, it is possible that the differen-
tial effects of levodopa vs. DA agonists can be related to the 
affinity of the different DA medications to D1 receptors.
There are several factors that influence the risk of 
developing LID. Not surprisingly, the administration of 
levodopa at a high dosage in somewhat advanced PD 
patients is associated with higher rate of LID (Parkinson 
Study Group, 1996). Kumar et al. (2005) found that early-
onset PD is accompanied by a higher occurrence of LID. 
They reported that after 5  years from the onset of PD, 
patients first diagnosed between 40 and 59  years of age 
have a 50% chance of developing LID, compared to the 
16% chance in patients diagnosed with PD after the age of 
70. The reason underlying this tendency is not completely 
obvious, although it may be due to age-related variations 
in levodopa dynamics in PD (Sossi et al., 2006).
Gender has also demonstrated to be a risk factor, 
with females three times more likely to develop LID than 
males are (Zappia et al., 2005). The authors suggest that 
this could be due to the female hormone estrogen, which 
may affect the individual’s sensitivity to levodopa. The 
existence and extent of nigral denervation (disease sever-
ity) are also important risk factors as nigral deterioration 
plays a role in the production of LID in a 1-methyl-4-phe-
nyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model of 
PD in monkeys (Di Monte et al., 2000). The monkeys in Di 
Monte et al. (2000) developed dyskinesias within weeks of 
starting levodopa, suggesting intensity of the nigral lesion 
as a significant risk factor. Additionally, when adminis-
tering a standard dose of levodopa, LID happens almost 
exclusively in patients with idiopathic PD. Normal people 
and those with other neurological diseases do not suffer 
LID after levodopa therapy (Chase et al., 1973).
In addition, studies found that the levodopa dosage 
is associated with the severity of LID: larger doses of levo-
dopa are accompanied also by extended dyskinesias (Nutt 
et al., 1992). However, dosage is not the only contributing 
factor of LID onset. Potts et al. (2014) found that LIDs do 
not appear in the early stages of DA treatment in MPTP 
monkeys but appear to be related to the severity of the 
MPTP PD symptoms. Additionally, in human populations, 
studies have revealed an increase in the frequency of LID 
over the course of the disease (Duvoisin, 1974;  Parkinson 
Study Group, 1996). Further, a recent study found that LID 
onset was not significantly different between a levodopa-
treated Italian cohort and an untreated Ghanaian cohort 
(Cilia et al., 2014). Additionally, the onset of LID appeared 
to be linked to disease duration. Sharma et al., (2006) have 
also demonstrated an association with weight loss and LID, 
where PD patients who develop LID are also more likely to 
have lost weight since the onset of PD. As not all patients 
on dopaminergic treatment show signs of LID (Fabbrini 
et al., 2009), there are likely other factors involved, such 
as genetics. Specific kinds of genetic polymorphism of the 
DA receptor D2 gene have been accompanied by decreas-
ing risk of developing peak-dose dyskinesias (Oliveri 
et  al., 1999). In a recent study by Kaplan et  al. (2014), a 
single nucleotide polymorphism on the DA transporter 
gene was also found to be associated with the risk of onset 
of LID. The adenosine A2A (ADORA2A) gene is located at 
chromosome 22q11.23 and encodes ADORA2A receptors. 
These receptors are predominantly distributed in stria-
tum and suppress the D2 receptors activity. Rieck et  al. 
(2015) reported a positive correlation between LID and the 
ADORA2A gene polymorphism rs2298383 and rs3761422. 
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This may be due to adenosine effect on release of DA in 
striatum.
Neural substrates of LID
Despite considerable improvement, the pathogenesis of 
LID is not completely understood. In the basal ganglia, it 
was found that abnormal function of either the striatum or 
subthalamic nucleus (STN) is associated with dyskinesia 
in unilateral 6-hydroxydopamine (6-OHDA) lesioned male 
Sprague-Dawley rats (Soghomonian, 2006). Other studies 
suggest that prefrontal cortex (Cerasa et  al., 2012) or cer-
ebellum (Kishore and Popa, 2014) dysfunction can lead to 
dyskinesia in PD patients. Rat experiments show evidence 
that altered activation of the premotor cortical area is the 
neural mechanism underlying LID (Halje et al., 2012; Richter 
et al., 2013). Using functional magnetic resonance imaging 
(fMRI) and an inhibition task, a reduction in activity of right 
inferior frontal cortex was observed when LID patients suc-
cessfully inhibited their response (Cerasa et  al., 2015a,b). 
Additionally, increased activity of medial frontal cortex 
caused by levodopa dissipated after an incorrect response 
in PD+LID patients (PD patients with LID), but not in PD-LID 
patients (PD patients without LID) (Cerasa et al., 2015a,b). 
Cerasa et al. (2015a,b) also stress the pivotal regulatory role 
of inferior frontal cortex on LID in PD patients. A resting 
state fMRI study revealed that the connectivity of the right 
inferior frontal cortex is positively related with the right 
putamen and negatively with the left motor cortex in the 
LID group, while the continuous repetitive trans magnetic 
stimulation of inferior frontal cortex diminish LID. Using 
fMRI, Herz et  al. (2015) assessed brain connectivity of PD 
patients after supplementation with one dose of levodopa. A 
positive correlation existed throughout movement suppres-
sion between later risk of developing LID and post-levodopa 
rise in brain connectivity between primary motor cortex and 
putamen (Herz et al., 2015). Additionally, altered levodopa 
connectivity between putamen and both presupplementary 
motor area and primary motor cortex act as a significant pre-
dictor for the severity of LID (Herz et al., 2015). Connectivity 
between the putamen and other cortical areas, however, did 
not predict LID severity (Herz et al., 2015).
Several studies implicate alterations to different neu-
rotransmitters for the occurrence of LID, including DA 
(D1, D2, and D3 receptors), serotonin (5HT), g-aminobu-
tyric acid (GABA), and glutamate (Bibbiani et al., 2005; 
Rylander et  al., 2010; Politis et  al., 2014). It was sug-
gested that sustained physiological stimulation caused 
by irregular administration of levodopa leads to down-
stream changes to striatal output in such a manner that 
triggers dyskinesias (Bibbiani et al., 2005). In addition, 
disruption to DA D2 receptors in the indirect pathway 
can cause disinhibition of the primary motor cortex (via 
pallidothalamocortical motor pathway), leading to LID 
(Rascol et al., 1998). Studies also found that overstimu-
lation of D1 receptors can cause dyskinesia (Aubert et al., 
2005; Berthet and Bezard, 2009; Berthet et  al., 2009; 
Moustafa et al., 2013), as well as alterations in both D1 
and D2 receptors (Iravani et  al., 2012). Specifically, Ye 
et  al. (2014) suggested that the oversuppression of D2 
receptors plays a pivotal role in the induction of LID. 
This was supported by the reduction in LID symptoms 
in a 6-OHDA model of PD in Sprague-Dawley rats when 
D2 receptor expression was increased. Additionally, 
Cote and Kuzhikandathil (2015) reported an association 
between LID and an abnormally increased expression of 
DA D3 receptors in the dorsal striatum.
Marín et  al. (2015) investigated the expression of pre-
proenkephalin (which is a marker of D2 receptors in the indi-
rect basal ganglia pathway) and preprodynorphin mRNA 
(which is not only a marker of D1 receptors in the direct basal 
ganglia pathway, but also a compensatory plastic change 
observed in LID). Marín et al. (2015) reported that the admin-
istration of 6-OHDA to rats elevated preproenkephalin with 
preserved preprodynorphin mRNA expressions in the stria-
tum. The initial induction of right-sided lesion reproduced 
a higher level of expression of preprodynorphin and pre-
proenkephalin mRNA in the subsequent left lesion side with 
more profound LID, suggesting that there is an increase in 
activity of D1 receptors in the direct basal ganglia pathway. 
Further, a positive correlation existed between LID and both 
preprodynorphin mRNA expression and orolingual dyskine-
sias in the bilateral model.
Positron emission tomography was used by Smith 
et al. (2015) to compare 5HT and DA systems in the globus 
pallidus in PD patients with LID (PD+LID), PD patients 
without LID (PD-LID), and healthy controls. Preserved 
binding of 5HT receptors was observed among PD+LID, 
while PD-LID patients exhibited a decrease in binding 
of 5HT receptors in globus pallidus, compared to healthy 
individuals. Further, selective 5HT reuptake inhibitors 
have been suggested to delay LID onset and reduce the 
severity of the symptoms (Mazzucchi et al., 2015). Cheshire 
et al. (2015), however, oppose the role of 5HT pathway in 
the pathogenesis of LID. Comparing brain samples from 
PD patients and healthy controls, they found preserved 
5HT in putamen, 5HT neurons in dorsal raphe nucleus and 
serotonergic transporters in corpus striatum, and reduced 
5HT in caudate among PD patients, similar to healthy 
controls. Importantly, no correlation existed between 
5HT markers and LID or its severity. Using the specific 
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radiological receptor binding autophagy radioligand [3H]
GR125743, Morin et al. (2015) found a positive correlation 
between serotonin receptor binding and the severity of 
LID in both PD patients and a MPTP monkey model of PD.
The hyperactivity of glutamatergic systems [using 
N-methyl-d-aspartate (NMDA) receptors] in the basal 
ganglia may also have a role in the occurrence of LID (Chase 
et al., 2003). Additional support for this theory arises from 
animal studies where the NMDA antagonist dextrophan 
combined with levodopa was found to reduce dyskine-
sias in MPTP-treated monkeys (Blanchet et al., 1996) and 
from clinical observations of the efficiency of amantadine, 
a weak NMDA antagonist, in treating LID (Rodnitzky and 
Narayanan, 2014). Interestingly, in rat models, the effects 
of NMDA antagonists are dependent on whether dyskine-
sia is due to impairment in the indirect or direct striatal 
pathway (Flores et al., 2014). An increase in striatal post-
synaptic glutamate-5 receptors (mGlu5) has been noted in 
PD patients and animal models of PD (Morin and Di Paolo, 
2014). Mellone et al. (2015) reported an abnormal ratio of 
GluN2A/GluN2B subunit of NMDA receptors in the stria-
tum of postmortem brain specimens from 16 PD patients, 
6-OHDA model of PD in male Sprague-Dawley rats, and 
MPTP monkey model of PD suffering from LID. There was a 
significant sole elevation of synaptic localization of GluN2A 
subunit among PD patients. LID in the two animal models 
benefited from the manipulation of scaffolding protein post-
synaptic density protein 95 of GluN2A subunits (Mellone 
et al., 2015). Thus, the manipulation of NMDA receptor sub-
units aiming to deteriorate synaptic GluN2A could be one 
of the future therapeutic modalities for LID. Further, dipra-
glurant and mavoglurant, two new glutamate antagonists 
that target mGlu5 receptors, are currently undergoing pre-
clinical testing trials for the treatment of LID (Rascol et al., 
2014). Both have been shown to reduce dyskinesia severity 
in MPTP macaque monkeys while also demonstrating anti-
Parkinsonian properties (Bezard et al., 2014). In addition to 
glutamate, postmortem studies found an increased concen-
tration of GABA(A) receptors in the internal globus pallidus 
in dyskinetic patients compared to nondyskinetic patients 
(Calon et al., 2003). Other studies implicate striatal GABA 
and other interneurons in the occurrence of LID (Levy and 
Hallett, 2002; Gittis et al., 2011).
Medications and deep brain 
 stimulation to treat LID
Pharmacological treatment of LID can take multiple 
directions: they may mimic the actions of levodopa with 
the hopes of reducing LID through different activation 
routes. They may also target other neurotransmitters that 
play a role on the striatal pathways such as glutamate 
and GABA. Novel treatments have taken a different path, 
instead focusing underlying genes [i.e. phosphodiesterase 
10A (PDE10A)] or cellular support compounds [i.e. doco-
sahexaenoic acid (DHA)]. Please refer to Table 1 for a list 
of drugs and their actions and effects on levodopa treat-
ment. In severe cases where the patient is unresponsive 
to medications, surgical interventions may be used. These 
may involve pallidotomy, subthalamotomy, or deep brain 
stimulation (DBS).
While LID appears to be the product of overstimulated 
DA receptors caused by levodopa, it may be exacerbated 
by the irregular stimulation from levodopa (Bibbiani et al., 
2005). Studies found that using continual infusion of 
levodopa showed success in treating patients with severe 
PD and revealed no increase in dyskinesia as compared 
to oral levodopa therapy (Nilsson et  al., 2001; Nyholm 
et al., 2005). Similar results were found with subcutane-
ous, intramuscular, or intravenous infusion of levodopa 
(Djaldetti and Melamed, 1996), although the exact reasons 
and mechanisms of the differential effects of methods 
of administration on LID are not known. Alternative DA 
agonists can minimize dyskinesias as found in an animal 
study using bromocriptine (Bédard et  al., 1986), ropin-
irole (van Boven et al., 2014), and apomorphine (Colosimo 
et al., 1994; Manson et al., 2002; Deleu et al., 2004). Addi-
tionally, drugs may reduce LID by targeting enzymes that 
break down levodopa. Using a rat model of PD, Marín et al. 
(2006) investigated the coadministration of entacapone, 
a chol-o-methyltransferase enzyme inhibitor (Agundez 
et al., 2013), with levodopa reducing more severe dyskine-
sia in rats when compared to levodopa alone. This action 
is believed to be caused by the extension of levodopa half-
life by entacapone (Marín et  al., 2006). This extension 
of levodopa may smooth out DA fluctuations, creating a 
similar effect as continuous levodopa infusion.
Alternative treatments for LID also target non-DA 
systems. Eltoprazine, a mixed 5HT 1AandB receptor 
agonist, has also been found to improve LID symptoms 
while maintaining motor coordination when administered 
with levodopa (Paolone et  al., 2015). Rosiglitazone, an 
antidiabetic drug, stimulates gamma subtype peroxisome 
proliferator-activated receptors in a unilateral 6-OHDA rat 
model of PD, which resulted in reduction of LID (Martinez 
et al., 2015). This effect may be mediated through a levo-
dopa-induced decrease in phosphorylation of extracellular 
signal-regulated kinase, dynorphin and zif-268, an imme-
diate early gene induced by D1 receptor oversensitivity, in 
the striatum of the lesioned side (Martinez et  al., 2015). 
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Table 1: Pharmacological treatments for levodopa induced dyskinesia.
Drug   Class   Antidyskinetic effect   Effect on levodopa 
treatment
  Human studies   Animal studies   Comments
Bromocriptine   DA receptor 
agonist
  Acts on the D2 
receptor
  No effect on levodopa 
efficacy
    Ogawa et al., 
1996; de Leeuw 
van Weenen 
et al., 2010
 
Entacapone   COMT inhibitor   No direct anti-
dyskinetic effect
  Compliments levodopa/
carbidopa treatment as it 
inhibits COMT, increasing 
levodopa efficacy
  Kuoppamaki 
et al., 2015
   
Ropinirole   DA receptor 
agonist
  Acts on the D2 
receptor, reducing 
the required dose of 
levodopa
  No effect on levodopa 
efficacy
  Adler et al., 
1997; van 
Boven et al., 
2014
   
Apomorphine   DA receptor 
agonist
  Acts on D2, D3, and 
D4 receptors
  Can replace or 
compliment levodopa 
treatment to enhance 
outcomes by stimulating 
D2, D3 and D4 receptors
  Colosimo 
et al., 1994; 
Manson et al., 
2002
   
Dipraglurant   mGlu receptor 
antagonist
  Inhibits mGlu 
receptor type 5
  No effect on levodopa 
efficacy
  Rascol et al., 
2014
   
Mavoglurant   mGlu receptor 
antagonist
  Inhibits mGlu 
receptor type 5
  No effect on levodopa 
efficacy
    Bezard et al., 
2014
 
Eltoprazine   5HT 1AandB 
receptor 
agonist
  Inhibits GABA 
neurons in the direct 
pathway
  No effect on levodopa 
efficacy
  Svenningsson 
et al., 2015
  Paolone et al., 
2015
  Results have 
been much 
stronger in rats 
and nonhuman 
primates than in 
PD patients
Rosiglitazone   Peroxisome 
proliferator-
activated 
receptors 
agonist
  Increases gene 
activation in D1 
receptors in the 
striatum
  No effect on levodopa 
efficacy
    Martinez et al., 
2015
 
PPI-1011   EP precursor   Increases DHA 
storage, improving 
neuronal function
  No effect on levodopa 
efficacy
    Grégoire et al., 
2015
 
This suggests that antidiabetic drugs such as rosiglitazone 
may ameliorate LID symptoms in PD patients. While elto-
prazine and rosiglitazone target alternative transmitters, 
they do have an indirect effect on the DA system.
PDE10A is one the subtypes of PDEs that repro-
duce degradation of cyclic adenosine monophosphate 
(cAMP) and cyclic guanosine monophosphate (cGMP). 
Thus, it modulates neuronal conductivity through con-
trolling the levels of these second messengers (Menniti 
et al., 2006). High levels of PDE10A were detected in the 
substantia nigra, corpus striatum, and globus pallidus 
(Coskran et  al., 2006). Additionally, Seeger et  al. (2003) 
stated a high expression of PDE10A in the striatal medium 
spiny neurons, which control the excitability of the basal 
ganglia, of male Sprague-Dawley rats.
In an LID model of unilateral 6-OHAD lesioned young 
male Sprague-Dawley rats, Giorgi et  al. (2008) stated 
that a significant bilateral declination of both cAMP and 
cGMP levels in globus pallidus, caudate putamen, and 
sensorimotor cortex areas was observed. Subcutaneous 
preadministration of the PDE inhibitor zaprinast reduced 
the degree of LID. This beneficial effect was medicated by 
partial preservation of cAMP and cGMP in globus palli-
dus, caudate putamen, and sensorimotor cortex in both 
sides through a reduction in cAMP and cGMP degradation 
(Giorgi et  al., 2008). Additionally, stereotaxic injection 
of PDE inhibitors into the corpus striatum of unilateral 
6-OHAD lesioned adult male Wistar rats also reduced LID 
(Picconi et al., 2011). This beneficial effect may be attrib-
uted to restoring of LID-induced altered glutamatergic 
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striatal synaptic plasticity through regulation of cGMP 
(Picconi et al., 2011).
Initial lower levels of both cAMP and cGMP were 
detected during increasing stage of LID in the corpus 
striatum of a unilateral 6-OHAD model of PD in male 
Sprague-Dawley rats, followed by their reduction during 
the decreasing and termination stages of LID (Sancesario 
et al., 2014). This could be elucidated by an increased deg-
radation of cGMP but not cAMP, as it was evident by a sole 
increase in the activity of cGMP PDE. Preserved highly 
expressed PDE10A in the basal ganglia after administra-
tion of levodopa in both LID and non-LID groups was 
manifested. Therefore, the PDE inhibitors had no role in 
the alleviation of LID symptoms. Yet, antagonizing the 
reduction in both cAMP and cGMP by preadministration 
of amantadine abolished the LID (Sancesario et al., 2014).
Positron emission tomography was used to assess 
PDE10A in the basal ganglia of 24 PD patients receiving 
levodopa in comparison to 12 healthy individuals (Nic-
colini et  al., 2015). Low levels of PDE10A were detected 
in the caudate, putamen, and globus pallidus among PD 
patients. Additionally, there was an inverse relationship 
between PDE10A level in these brain regions and both 
disease duration and Unified Parkinson’s Disease Rating 
Scale part-III motor scores (Niccolini et al., 2015). PD-LID 
patients showed decreased levels of PDE10A, and PD+LID 
patients also had even lower PDE10A concentrations in 
the caudate, substantia nigra, and motor thalamic nuclei 
(Niccolini et al., 2015). The findings of Niccolini et al. (2015) 
on a human PD population contrast findings from the rat 
models. This may reflect the complexity of PD in humans 
compared to the unilateral 6-OHDA rat model of PD.
Recent research has targeted DHA supplements as a 
viable treatment for PD (Yakunin et al., 2012; Blanchard 
et al., 2014; Lee et al., 2015). DHA is an omega acid and 
is one of the main building blocks of the human brain, 
making up approximately 8% of its dry weight. It is also 
pivotal in normal cellular functioning (Muskiet et  al., 
2006). DHA supplements have been shown to slow cogni-
tive decline in the elderly as well as lower the risk of devel-
oping Alzheimer’s disease (Cunnane et al., 2013). In animal 
models of PD, DHA has a neuroprotective effect, decreas-
ing the rate of DA receptor loss (Hacioglu et  al., 2012). 
Further, Grégoire et al. (2015) tested the effect of ethanola-
mine plasmalogens (EPs) on LID in a MPTP monkey model 
of PD. EP has many cellular functions, one in particular is 
its ability to maintain high levels of polyunsaturated fats, 
such as DHA (Nagan and Zoeller, 2001). Grégoire et  al. 
(2015) treated the monkeys with either DHA or EP. The EP 
was administered via PPI-1011, a specialized EP precur-
sor that also contains DHA. When given DHA alone, LID 
symptoms begun to recede after 10 days; however, when 
PPI-1011 was administered, symptoms receded after 2 days 
(Grégoire et al., 2015). These data suggest that while DHA 
is beneficial for the treatment of LID, it may be much more 
effective when given with EP. The action responsible for 
the increase in DHA efficacy may be due to the effect that 
EP has on polyunsaturated fats, or it may be one of its 
many other functions (see Nagan and Zoeller, 2001, for a 
review).
In severe cases, neurosurgery may be a necessary 
course of treatment. These procedures may include pal-
lidotomy or subthalamotomy or DBS. This procedure 
involves two electrodes being inserted into the target 
areas, which deliver pulses of electricity at a set fre-
quency. DBS of the internal globus pallidus (GPi) or STN 
showed significant success in treating LID. Anderson 
et al. (2005) reported a reduction of dyskinesias by DBS 
of both the GPi and STN. This reduction was not because 
of the diminished requirement for levodopa, as the STN 
group had a greater reduction in dosage, while the GPi 
group exhibited a greater reduction in LID. Importantly, 
the effects of DBS on LID can still be visible after 7 years 
of treatment (Tsai et al., 2013). Similar findings have also 
been reported with patients with LID, with symptoms 
being significantly reduced after bilateral subthalamic 
DBS (Kim et  al., 2015). The actual mechanisms of DBS 
on LID are unclear; however, there are several hypoth-
eses, the latest of which suggests a disruption effect of 
the stimulation on the firing of neurons in the target 
area (Chiken and Nambu, 2016). With the loss of 75% of 
DA  receptors in the striatum, the stimulations from these 
receptors become inconsistent. To counter this, levodopa 
is added to the system. This in turn causes these recep-
tors to produce pulsatile stimulation leading to abnormal 
striatal output, which causes LID (Jenner, 2008). Replac-
ing levodopa with other DA agonists with longer action 
durations creates a more continuous stimulation that is 
a closer match to a normal striatum (Jenner, 2008). A 
similar mechanism may be behind the beneficial effects 
of DBS. As the striatum feeds both the direct and indirect 
DA pathways, the abnormal stimulation may be passed 
downstream to these areas. DBS of the STN or GPi may 
disrupt the abnormal stimulation and smooth it out with 
a more continuous one (Chiken and Nambu, 2016).
Jourdain et al. (2015) investigated the effect of unilat-
eral subthalamotomy on glutamate receptors of the basal 
ganglia of a MPTP model of PD in macaque monkeys. 
Their findings revealed that unilateral subthalamotomy 
was capable of antagonizing levodopa-induced elevated 
binding of NMDA receptors bilaterally in the corpus 
striatum and contralaterally in the globus pallidus. 
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Subthalamotomy reduced specific binding of metabo-
tropic glutamate (2/3) receptor bilaterally in the corpus 
striatum and globus pallidus; both actions decreased LID 
symptoms in the MPTP model of PD.
Conclusion
LID is a common side effect of DA treatment for PD. LID 
was found to be caused by abnormalities to both D1 and 
D2 receptors on the striatum. This may cause abnormal 
striatal signals, which are then fed down the direct and 
indirect pathways of the BG and then carried to various 
areas in the cortex involved in motor planning and inhibi-
tion. Non-oral administration of levodopa (including sub-
cutaneous, intramuscular, and intravenous infusion) has 
a lower chance of causing LID (Djaldetti and Melamed, 
1996) than the traditional oral administration does. LIDs 
have also been shown to be reduced by supplementing DA 
treatment with drugs that target other neural transmitters 
such as 5HT agonists, glutamate antagonists or enzymes, 
or fatty acids. These treatments have been shown to 
improve LID by increasing the efficacy of levodopa, result-
ing in lower dosage of levodopa required.
The aforementioned studies show that LID is associ-
ated with a complex neurochemical mechanism involv-
ing DA, glutamate, 5HT, and GABA. Neural studies also 
suggest that LID involves abnormalities to many brain 
areas, including different subregions of the basal ganglia 
(including the striatum and STN), prefrontal cortex 
(Cerasa et al., 2012), premotor cortical area (Halje et al., 
2012; Richter et  al., 2013), and cerebellum (Kishore and 
Popa, 2014). Future research should focus on exact con-
tribution of different neurotransmitters and brain regions 
to LID. Due to the number of factors involved in the onset 
of LID, employing a computer model representing the stri-
ato-cortical pathways may allow researchers to isolate the 
influence the pathway has on the prefrontal cortex, motor 
area and cerebellum.
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